Allergan (NYSE:AGN) and women’s health nonprofit pharma company Medicines360 touted 4-year data today from an ongoing pivotal trial for its Liletta intrauterine contraceptive. The system is approved for the prevention of pregnancy for up to 3 years.
More than 1,500 women ranging from 16 to 45 years old were enrolled and studied in the group’s clinical trial. The abstract, which was presented at the American College of Obstetricians and Gynecologists annual clinical and scientific meeting, includes safety outcomes and 4-year pregnancy rates from the ongoing trial.
The Pearl Index, which describes the number of unintended pregnancies per 100 women over 1 year of use, was 0.15 among women ages 16 to 35.